Genomic Vision Announces the Availability of the Prospectus Relating to the Financing Program Concluded With Winance for a Maximum Amount of €12 Million

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News:

Genomic Vision (Paris:GV) (the “Company” - FR0011799907 - GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces the availability of the prospectus relating to the financing program concluded with Winance in form of convertible notes with equity warrants attached (OCABSA) for a maximum amount of €12 million.

The prospectus approved by the Autorité des marchés financiers (AMF) on February 9, 2021 under No. 21-028, consisting of a Securities Note and a Universal Registration Document filed with the AMF under No. R21-002, is available at the Company's registered office (80/84 Rue des Meuniers, 92220 Bagneux), on the Company's website (www.genomicvision.com) and on that of the AMF (www.amf-france.org).

It should be noted that on June 15, 2020, the Company announced the signing of a contract with Winance on June 11, 2020 to setting up a financing line by issuing convertible bonds (the “OC”) into ordinary shares to each of which will be attached a share subscription warrant (the “BSA” and together with the shares to which they are attached the “ABSA” and with the OC the “OCABSA”), for a maximum total amount of 12 million euros, it being specified that neither the OC nor the BSA will be listed.

This financing is intended to ensure the Company's continuity beyond May 2021 and to provide financial visibility until 2022 by granting it additional resources to secure and pursue its development and to cover the Company's current and structural expenses.

The extraordinary general meeting of the Company which met on October 30, 2020 approved the implementation of this financing and a first tranche of OCABSA for an amount of €0.8 million was already draw down last November.

Filing of a prospectus was required as the issuance of one or more additional tranches of OCABSA may lead to the issuance of a number of shares that may exceed 20% of Genomic Vision's share capital over 12 months.

***

ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit www.genomicvision.com.

***

Member of the CAC^® Mid & Small and CAC^® All-Tradable indexes

FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on February 9, 2021 under reference number R.21-002, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

Genomic Vision
Dominique Remy-Renou
CEO
+33 1 49 08 07 51
investisseurs@genomicvision.com

Ulysse Communication
Press Relations
Bruno Arabian
+33 1 42 68 29 70
barabian@ulysse-communication.com

NewCap
Investor Relations & Strategic Communications
+33 1 44 71 94 94
gv@newcap.eu